Modality
Gene Editing
MOA
Cl18.2
Target
IL-23
Pathway
Incretin
Prostate CaHuntington'sFL
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
~Mar 2018
→ ~Jun 2019
NDA/BLA
~Sep 2019
→ ~Dec 2020
Approved
Mar 2021
→ Oct 2025
ApprovedCurrent
NCT08880835
2,865 pts·Prostate Ca
2021-03→TBD·Recruiting
NCT03520771
2,185 pts·FL
2024-04→2025-10·Active
5,050 total pts2 indications
CompletedCurrentUpcoming
Catalysts (1)
2025-10-215mo agoPh3 Readout· FL
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Approved
Recruit…
Approved
Active
Catalysts
Ph3 Readout
2025-10-21 · 5mo ago
FL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08880835 | Approved | Prostate Ca | Recruiting | 2865 | HbA1c |
| NCT03520771 | Approved | FL | Active | 2185 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 | |
| Talafotisoran | Blueprint Medicines | Phase 2/3 | IL-23 |